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Abstract
Introduction Portal vein embolization (PVE) is a well-
established technique to enhance functional hepatic
reserves of segments II and III before curative extended
right hepatectomy for tumors of the right liver lobe.
However, an adequate hepatopetal flow of the left lateral
portal vein branches is required for a sufficient PVE-
associated hypertrophy.
Case report Here, we report a 65-year old patient suf-
fering from a locally advanced intrahepatic cholangiocar-
cinoma in the right liver lobe and segment IV. A curative
extended right hepatectomy after preoperative PVE of liver
segments IV–VIII was initially impossible because of
partial thrombosis of the left lateral portal vein branches
resulting in an ischemic-type atrophy of segments II and
III. However, due to a massive hypertrophy of the caudate
lobe following PVE of liver segments IV–VIII, subsequent
extended right hepatectomy with intraoperative thrombec-
tomy of segments II and III was made possible.
Conclusions To our knowledge this is the first case in
which an extended right hepatectomy for a liver malig-
nancy, in the presence of atrophic left lateral section, was
made possible by a massive PVE-associated hypertrophy of
the caudate lobe.
Keywords Extended right hepatectomy  Portal vein
embolization  PVE  Cholangiocarcinoma
Introduction
Extended right hepatectomy is required to obtain tumor-
free surgical margins in up to one-third of oncological liver
resections [1, 2]. However, major hepatectomies are asso-
ciated with increased morbidity and mortality because of
postoperative liver failure (PLF) [3, 4].
Intrahepatic cholangiocarcinoma (IHC) represents the
second most common primary liver cancer and its inci-
dence has risen over the past decades in Western countries
[5]. Curative resection represents the treatment of choice
for IHC, as it is the only chance of long-term survival with
5-year survival rates ranging between 21 and 35 % [6–10].
Results of radio- and conventional chemotherapy are lim-
ited with a median survival of 12 months [11–14].
Due to the mass-forming character of this tumor entity
and the late onset of symptoms, patients are frequently
diagnosed at an advanced tumor stage with the need of an
extended right hepatectomy. In case of a predicted too low
future liver remnant volume (FLRV) of left lateral liver
segments II and III, the safety of major hepatic resection
can be significantly improved by preoperative selective
portal vein embolization (PVE) of the right liver lobe.
An adequate hepatopetal flow of the left lateral portal
vein branches is required for an effective PVE-associated
hypertrophy of segments II and III. Here, we report a
patient with an advanced IHC in the right liver lobe and
segment IV and a partial portal vein thrombosis of liver
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segments II and III after selective PVE of liver segments
IV–VIII resulting in an ischemic-type left lateral liver
atrophy. However, extended right hepatectomy following
PVE was made possible due to a massive hypertrophy of
the caudate lobe.
Case report
A 65-year old female patient was referred to our center in
April 2010 with a histopathologically confirmed, moder-
ately differentiated cholangiocarcinoma of the right liver
lobe and segment IV. The initial symptoms of the patient
were reported as upper abdominal tension. The patient
appeared to be in a good general condition and, except for a
cholecystolithiasis, no further diseases were evident. The
blood tests revealed elevated serum levels for carbohydrate
antigen 19-9 (136 U/ml), normal findings for alpha-1-
fetoprotein and carcinoembryonic antigen, and slightly
elevated liver enzymes with a normal bilirubin level
(Table 1).
Computed tomography (CT) of the abdomen showed a
tumor spreading over liver segments IV–VIII with a
maximum diameter of 9 cm (Fig. 1a). Consecutive CT
volumetry of the liver revealed a total liver volume (TLV)
of 1,800 cm3 and an FLRV (liver segments I–III) of only
300 cm3. The tumor volume was 430 cm3. The TLV
excluding tumor volume was 1,370 cm3. This made a ratio
of FLRV per TLV excluding tumor volume of 21.9 %. In
addition, a preoperatively performed biopsy of the liver
revealed fibrotic tissue and intracytoplasmatic siderosis.
The caudate lobe and left lateral segments II and III were
free of tumor. The diagnostic evaluation revealed no
extrahepatic tumor manifestation. In the liver hilus, the
portal vein was in direct proximity to the tumor mass. The
common hepatic artery and the extrahepatic portal vein
showed no abnormalities. Furthermore, the portal vein
branch to segment I diverted in direct proximity to the
bifurcation of the main portal vein trunk (Fig. 1e). Due to
insufficient FLRV an embolization of the portal branches
to liver segments IV–VIII was performed (Fig. 1d, e).
Because of an increased risk for an accidental embolization
of the left-sided portal vein branches to segments II and III
we did not perform initial embolization of segment I.
Furthermore, an embolization of the caudate lobe would
have additionally deprived the future liver remnant (FLR)
from valuable healthy volume. We used non-calibrated
particles to embolize the portal vein branches. Histoacryl
coils or vascular plugs were also avoided because of the
risk of accidental embolization of the left-sided liver seg-
ments, which might eventually compromise a successful
hypertrophy and render the hepatic resection impossible.
Three weeks after embolization a CT volumetry of the
liver displayed a FLRV of liver segments I–III of 380 cm3
and a TLV of 1,709 cm3. Interestingly, liver hypertrophy
was evident only in the caudate lobe, but not in liver
segments II and III where the CT scan revealed a con-
striction of the portal branches to liver segments II and III
to be likely responsible for an inadequate left lateral
hypertrophy. Prior to surgery it remained unclear whether
the constriction of the left portal branches was due to
tumor-related thrombosis or infiltration.
It was decided to perform an explorative laparotomy,
where the tumor manifestation in liver segments IV–VIII
was confirmed (Fig. 2a). No evidence for extrahepatic
tumor dissemination or lymph node metastases was found.
Further exploration confirmed a massive hypertrophy of the
caudate lobe with a pre-existing atrophy of liver segments
II and III (Fig. 2b). Thrombosis of the portal vein to seg-
ment II and III, as suspected in the CT scan, was confirmed
by intraoperative ultrasound.
Preparation and exposition of the portal vein bifurcation
was completed, followed by a thrombectomy of the left
portal vein. A lymphadenectomy from the hepatic hilum to
Table 1 Liver function 1 day
before and after PVE as well as
1 day before hepatic resection
and on postoperative days 2
(POD 2) and 14 (POD 14)
ASAT aspartate amino




Normal values PVE Hepatic resection
1 day before 1 day after 1 day before POD 2 POD 14
Bilirubin \17.1 lmol/l 5.9 11.4 8 12.6 11.4
Total protein in serum 66.0–87.0 g/l 69.9 72.5 75.2 60.1 59.3
Albumin in serum 35–52 g/l 44.5 44.4 47.7 30 29.5
ASAT 0.17–0.60 ukat/l 0.71 1.28 0.63 5.08 0.53
ALAT 0.17–0.60 ukat/l 0.64 1.54 0.67 6.79 0.75
AP 0.58–1.74 ukat/l 2.93 3.19 3.21 1.64 1.66
GGT \0.65 ukat/l 3.44 3.67 4.28 1.95 2.14
Lipase \1.0 ukat/l 0.63 0.56 0.97 1.88 1.26
Creatinine 45–84 lmol/l 50 48 56 43 91
Prothrombin time [70 % 118 122 113 69 91
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the celiac trunk was also performed. Even after portal
thrombectomy, a very low blood flow was noted in the
portal branches to liver segments II and III, likely due to a
tumor-associated portal vein stenosis. The caudate lobe
displayed a significant hypertrophy with powerful perfu-
sion via both portal vein and proper hepatic artery.
Fig. 1 a Computed tomography (CT) of the abdomen displaying an
extended tumor manifestation prior to portal vein embolization. b CT
of the abdomen 3 weeks after portal vein embolization. c CT of the
abdomen 8 weeks after PVE and directly before extended right
hepatectomy. d Antegrade transhepatic portography (with 4F pigtail
catheter in the main portal vein trunk) showing normal contrasting of
the patient’s liver. e Antegrade transhepatic portography (with 4F
sidewinder catheter in the main portal vein trunk) showing no more
contrasting of the right-sided liver parenchyma. f CT of the abdomen
3 months after extended right hepatectomy and curative resection.
Black arrow tumor-free portal vein branches to segments II and III
(a); a tumor-related partial thrombosis of the portal vein branches to
segments II and III (b). Block arrow segment I prior to embolization
(a), after extensive hypertrophy following embolization (b, c).
Dashed line border between segment II/III and segment I. T tumor,
Seg I liver segment I
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The operation was terminated as an exploratory lapa-
rotomy due to the ischemic-type atrophy of segments II and
III associated with an expected marginal residual liver
function of the FLR and an increased risk of PLF. The
analysis of the intraoperative frozen sections and the defi-
nite histology of the thrombus and the excised lymph nodes
showed no evidence of tumor manifestation. A control
magnetic resonance imaging of the liver displayed a
renewed closure of the portal vein branches to segments II
and III.
Four weeks after the laparotomy and 7 weeks after PVE,
another CT scan of the abdomen was performed for re-
staging and renewed volumetric analysis. Again the CT
scan revealed a partial thrombosis of the portal branches to
segments II and III (Fig. 1b); however, the tumor showed
no progression with no tumor extension to segments II and
III or to the caudate lobe. The CT volumetry revealed a
FLRV for liver segments I–III of 400 cm3 and a TLV of
1,250 cm3 (tumor volume excluded). This made a ratio of
FLRV per TLV excluding tumor volume of 32 %.
Hypertrophy of the FLR was solely due to an enlargement
of segment I (Figs. 1c, 2c). Despite the ischemic-type
atrophy of segments II and III we decided to perform an
extended right hepatectomy with curative intent.
During the second operation, we explored the abdominal
cavity and excluded extrahepatic tumor manifestations. As
the intraoperative ultrasound confirmed the restriction of
the tumor to segments IV–VIII, we affirmed the indication
to perform an extended right hepatectomy. Parenchymal
transection was performed using an ultrasonic dissection
device (Cavitron Ultrasonic Surgical Aspirator, CUSA,
Valleylab, Boulder, CO, USA) without any intraoperative
Fig. 2 a Tumor manifestation in the right liver lobe before resection.
b Extensive hypertrophy of segment I, atrophic left lateral section
(segment II and III) and the already isolated right hepatic artery prior
to division. c Situs after hepatic resection with prominent caudate
lobe, atrophic segments II and III and stump of the right hepatic artery
after division. d Hepatectomy specimen after curative resection.
T tumor, O m Omentum majus, block arrow segment I, black arrow
segments II and III, r h a right hepatic artery, S stomach
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complications. Due to a risk of biliary leakage a T drain
was routinely inserted in the main bile duct for decom-
pression and easy access cholangiography.
In the postoperative course no signs of insufficient
liver function were notable. During the postoperative stay
in the intensive care unit the patient did not develop any
significant complications. Ten days after resection, the
patient developed a small abscess at the resection surface
which was successfully treated by percutaneous drainage.
There was no bilioma or bile leak evident. The postop-
erative duplex ultrasound of the liver revealed a powerful
orthotopic flow of the left hepatic artery and of the
hepatic veins and no evidence for central portal vein
thrombosis but a persistent thrombosis in the left portal
vein trunk. The conclusive pathological result showed a
poorly differentiated cholangiocarcinoma without lymph
node metastases (UICC stage II), hepatocellular steatosis
and siderosis as well as cholestasis and cholangitis. The
resection was categorized as formally curative (Figs. 1f;
2c, d). After a total postoperative hospitalization of
30 days the patient was dismissed in good general con-
dition. The follow-up visits at 6, 12 and 18 months after
resection revealed normal liver function and no evidence
of recurrent disease.
Discussion
Liver resection represents the only curative treatment
option for IHC and is currently considered as the treatment
of choice in this tumor entity. Studies about the efficacy of
liver resection in patients with IHC showed long-term
survival rates ranging from 30-60 % at 5 years after
resection [15–17]. Even in the presence of a more
advanced tumor stage, partial hepatectomy can provide
long-term survival in a considerable share of patients and
the growing experience in liver surgery facilitates extended
hepatectomies and provides a chance of cure in formerly
non-resectable liver malignancies [15]. The published
results of large series of patients who received liver
resection within the last 2 years underlined not only the
therapeutic efficacy of this treatment but also its safety.
The mortality rate even after major liver resections is
mostly\5 % in high-volume centers [18]. Hepatic surgery
in the current era is regarded as a safe procedure, and its
role in primary and secondary liver cancers is well estab-
lished [19].
However, PLF remains a potentially life-threatening
complication and often proves fatal, especially after major
hepatectomy [18]. The risk of PLF depends on the quality
of the parenchyma and the volume of the remnant liver.
Once liver failure is established, no reliable disease-
specific therapy is currently available and liver transplan-
tation is mostly contraindicated in these patients, resulting
in reported mortality rates of 60-80 % [20, 21]. Thus, a
sufficient FLRV is crucial for the success of major hepa-
tectomies in these patients. Few treatment modalities are
established to minimize the risk of postoperative liver
insufficiency by improving liver function and the remnant
volume before major hepatectomies, such as PVE and
selective biliary decompression in patients with biliary
stasis [22]. Recently, novel strategies have been proposed,
i.e., inclusive CD133? hematopoietic stem cells therapy,
which seems to positively impact overall outcomes after
extended right hepatectomy or in situ split techniques in
combination with portal vein ligature [23–25].
Here, we propose a selective hypertrophy of the caudate
lobe as a novel approach to facilitate extended right hep-
atectomy in patients with large tumors of the right liver
lobe. Extended right hepatectomy may be considered
impossible in cases of ischemic-type atrophy of left lateral
segments. However, in contrast to liver segments II and III,
the caudate lobe appeared well perfused and of good
parenchymal quality in the present patient. Due to a sig-
nificant hypertrophy of segment I during the post-inter-
ventional course following PVE, extended right
hepatetcomy became feasible with no major complications
apparent postoperatively. In particular, the liver function
did not reveal any signs of significant insufficiency in spite
of the atrophy of segments II and III.
This case is of major interest for patients with severely
limited left lateral liver function scheduled for uni- or
bilobular hepatectomies. These patients are widely exclu-
ded from curative treatment strategies due to the antici-
pated risk of PLF. Therefore, an induction of hypertrophy
of segment I could be a promising approach and, unless the
diagnosis is hilar cholangiocarcinoma, may provide a suf-
ficient remnant liver function to perform curative liver
resection. How can hypertrophy of segment I be induced
tactically? Aware of the fact that isolated, massive hyper-
trophy of segment I following PVE is possible, initial
embolization of this segment could be avoided. In selected
patients, one could consider initial embolization of seg-
ments 4–8 only, thus awaiting potential hypertrophy
induction of segment I.
In conclusion, extended right hepatectomy in the pre-
sence of thrombosis of the left portal vein branches to
segments II and III is feasible if liver segment I reveals an
adequate hypertrophy. To our knowledge, this is the first
case in which an extended right hepatectomy was made
possible by massive PVE-associated hypertrophy of the
caudate lobe. Therefore, atrophy of segments II and III may
not represent a general contraindication to extended right
hepatectomy.
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